Our Opinion

Caribou Biosciences Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“On day 0, each cohort of animals received a single dose of either PBS, the conventional allogeneic CD19 CAR-T cells, or CB-010 cells. By day 14 following dosing (D14 post CAR-T), animals that received PBS had become more metastatic, whereas both CD19-specific CAR-T cell therapies had eradicated the established tumors.” (Page 138) Read the full document

Company Description

Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer.

Company Website: https://www.cariboubio.com